Celldex Therapeutics, Inc. — Director's Dealing 2021

Jun 21, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2021-06-17

Reporting Person: Marucci Anthony S (Director, President & CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-17	Incentive Stock Option (right to buy)	$28.00	A	224000	Acquired	2031-06-17	Common Stock (224000)	Direct

Footnotes

F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F2: 25% vest on June 17, 2022 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.